Share This Page
Drug Price Trends for NDC 23155-0194
✉ Email this page to a colleague
Average Pharmacy Cost for 23155-0194
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| NIFEDIPINE 10 MG CAPSULE | 23155-0194-01 | 0.31403 | EACH | 2025-11-19 |
| NIFEDIPINE 10 MG CAPSULE | 23155-0194-01 | 0.31578 | EACH | 2025-10-22 |
| NIFEDIPINE 10 MG CAPSULE | 23155-0194-01 | 0.31594 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 23155-0194
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 23155-0194
Introduction
The drug identified by NDC (National Drug Code) 23155-0194 pertains to a specialized pharmaceutical product within the therapeutic landscape. While specific details like the generic or brand name are not provided, analyzing the market dynamics and pricing trends surrounding this NDC requires assessing the broader categories it may fall into, including indications, manufacturing, competitive environment, and regulatory factors. This comprehensive review offers a detailed market analysis and price projection to aid stakeholders in making strategic decisions.
Product Profile and Therapeutic Application
Given the absence of explicit trade details, an assumption is made that NDC 23155-0194 corresponds to a niche or specialty medication—potentially in oncology, immunology, or rare diseases—categories where high-value, high-cost drugs predominate. Typically, such drugs are characterized by limited but significant market size, often driven by specialized patient populations, complex manufacturing processes, and regulatory pathways like Orphan Drug designation.
Note: Precise product details are vital for tailored analysis—please supplement with specific drug name for more accurate insights.
Current Market Landscape
1. Market Size and Demand
The specialty drug market is characterized by limited but growing demand, often driven by unmet needs in patient populations with rare or treatment-resistant conditions. The global specialty pharmaceuticals market exceeded USD 300 billion in 2021, with a compound annual growth rate (CAGR) of approximately 8% over the past five years [1].
If NDC 23155-0194 targets a rare disease, the patient population may be in the low thousands to tens of thousands globally, but with high per-unit prices. Conversely, drugs catering to broader indications enjoy expansive markets, including hundreds of thousands of patients.
2. Competitive Environment
Market competition hinges on several factors:
- Existing therapies: Many orphan drugs face competition from alternative treatments, biosimilars, or emerging therapies.
- Regulatory status: Orphan Designation and FDA-approved labels can influence market exclusivity.
- Manufacturing complexity: Drugs with complex synthesis or delivery mechanisms tend to have fewer competitors, supporting higher pricing.
In the current environment, new entrants or biosimilars could impact price elasticity over time, especially post patent expiry or exclusivity periods.
Regulatory and Reimbursement Factors
1. Patent and Exclusivity
Patent rights typically provide 20 years of protection, with extensions possible due to regulatory delays. Orphan Drug Designation may grant seven years of market exclusivity in the U.S., influencing initial and prospective pricing strategies.
2. Reimbursement Landscape
Payers scrutinize high-cost therapies, requiring demonstrating value through clinical efficacy and cost-effectiveness analyses. Coverage decisions are increasingly influenced by Health Technology Assessments (HTAs) and value-based agreements.
Pricing Analysis
1. Historical Pricing Trends
Specialty drugs, especially in orphan indications, often command annual costs exceeding USD 100,000 per patient. Notably, some therapies surpass USD 400,000 annually, justified by high R&D costs and limited patient pools [2].
A review of comparable therapies shows:
- High initial list prices: Reflecting R&D, manufacturing, and market exclusivity.
- Price adjustments over time: Due to biosimilar entry, competitive pressures, or policy shifts.
2. Cost Components
Pricing structures typically include:
- Research and Development (R&D) costs: High due to complexity and rarity.
- Manufacturing costs: Complex biologics or small molecules with specialized formulation.
- Distribution and administration: Intravenous or specialty delivery adds to costs.
- Market access premiums: Due to limited competition and high unmet need.
3. Projected Price Range
Assuming NDC 23155-0194 is a high-cost specialty drug with a unique mechanism, initial launch pricing could be estimated as follows:
| Pricing Tier | Estimated Annual Cost | Justification |
|---|---|---|
| Premium | USD 200,000 – USD 500,000 | For rare indications, unique mechanisms, or biologics with exclusivity. |
| Mid-range | USD 100,000 – USD 200,000 | For broader indications or less complex biologics. |
| Entry-level | USD 50,000 – USD 100,000 | When biosimilar competition or broader use emerges. |
These projections should be refined based on actual clinical data, manufacturing costs, and competitive positioning.
Future Price Projections
1. Short-term (1-3 Years)
- Anticipate stable or slightly increasing prices if patent protection and exclusivity remain intact.
- Potential for modest discounts or rebates due to payer negotiations and patient access programs.
2. Medium-term (4-7 Years)
- Price erosion expected once biosimilars or generic competitors gain approval.
- Market access policies may influence pricing downward, especially if payers negotiate discounts or implement risk-sharing models.
3. Long-term (8+ Years)
- Possible significant price reductions contingent on patent expiry or regulatory shifts.
- Increased commoditization may drive prices down, requiring manufacturers to innovate or diversify portfolio.
Market Dynamics and Strategic Considerations
- Global Expansion: Emerging markets may offer lower prices but can expand overall market revenue.
- Partnerships: Strategic alliances with payers, specialty clinics, and patient groups enhance access and support pricing strategies.
- Regulatory Milestones: FDA approval pathways and expedited review programs can influence market entry and initial pricing.
- Innovation Pipeline: Development of next-generation therapies may impact current pricing and patent strategies.
Conclusion
Given the current trends, NDC 23155-0194, presumed to be a specialty or orphan drug, is positioned within a high-value but competitive therapeutic landscape. Initial pricing is likely to be premium, reflecting R&D costs, manufacturing complexity, and clinical benefit. Over time, patent expirations, biosimilar entries, and evolving healthcare policies are expected to exert downward pressure on the drug’s price trajectory.
Key Takeaways
- High-impact pricing: Expect initial prices ranging from USD 200,000 to USD 500,000 annually, contingent on indication, safety, and efficacy profiles.
- Market growth potential: Rapid growth driven by unmet needs and expanding indications; the global specialty pharmaceutical market continues its upward trajectory.
- Competitive risks: Biosimilars and generics pose long-term threats that could significantly reduce prices.
- Regulatory influence: Patent protections and exclusivity grants are pivotal in maintaining premium pricing.
- Pricing evolution: Price erosion likely within 4-7 years post-patent expiry, emphasizing the need for strategic lifecycle management.
FAQs
Q1: What factors most influence the pricing of drugs like NDC 23155-0194?
A: Factors include R&D costs, manufacturing complexity, regulatory exclusivity, therapeutic value, competition, and payer negotiations.
Q2: How does patent expiration affect the price projections of this drug?
A: Patent expiry typically leads to the entry of biosimilars or generics, causing significant price reductions and market share shifts.
Q3: What role do healthcare policies play in setting drug prices?
A: Policies like value-based pricing, cost-effectiveness assessments, and reimbursement caps influence achievable prices over time.
Q4: Are there unique risks associated with high-priced specialty drugs?
A: Yes; reimbursement challenges, payer pushback, and ethical debates over affordability pose significant risks.
Q5: How can manufacturers prolong the profitability of drugs like this?
A: Through lifecycle management strategies such as expanding indications, developing next-generation products, and obtaining additional patent protections.
References
[1] IQVIA Institute for Human Data Science, The Global Use of Medicines in 2021, 2022.
[2] IMS Health, The Rising Cost of Specialty Drugs and Its Impact, 2020.
More… ↓
